Drug Consultations and Policies – Rare Autoinflammatory Conditions Community

Canakinumab for treating periodic fever syndromes: TRAPS, HIDS/MKD and FMF (ages 2 years and older) [March 2020]

CRYOPYRIN ASSOCIATED PERIODIC SYNDROME (ALL AGES) 2013/14

Clinical Commissioning Policy
Tocilizumab for the treatment of adult-onset Still’s disease
refractory to second-line therapy (adults) [210801P] (URN: 1609)

UPDATED: August 2021

Clinical Commissioning Policy: Anakinra to treat periodic fevers and autoinflammatory diseases (all ages) [2018].

Baricitinib for use in monogenic interferonopathies (adults and children 2 years and over) [2021]

Clinical
Commissioning
Policy: Rituximab for
cytopaenia
complicating primary
immunodeficiency [2016]

Allogeneic Haematopoietic Stem Cell Transplant for Primary Immunodeficiencies (all ages)

Clinical Commissioning Policy:
Treatment of Acute Attacks in
Hereditary Angiodema (Adult)
April 2013
Reference: NHSCB/B09/P/b